We are BrainsWay

What BrainsWay is all about

BrainsWay is dedicated to developing and providing advanced solutions for brain disorders using its revolutionary technology, Deep Transcranial Magnetic Stimulation (Deep TMS). The company was established in 2003, became a public company traded on the Tel-Aviv Stock Exchange in January 2007 and NASDAQ (BWAY) in April 2019. BrainsWay’s treatment is based on patents filed jointly by the company and the U.S. National Institutes of Health (NIH), and held exclusively by BrainsWay.

BrainsWay is FDA-cleared for treating adult patients suffering from Major Depressive Disorder (MDD) who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288). BrainsWay is also approved in Canada for the treatment of Major Depressive Disorder (Health Canada Licence No. 90504).

BrainsWay is also FDA-cleared as an intended adjunct treatment for adult patients suffering from Obsessive-Compulsive Disorder (OCD) (FDA De Novo No. DEN170078).

Furthermore, BrainsWay holds CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions, including Post-Traumatic Stress Disorder (PTSD) and Alzheimer’s Disease (AD).

BrainsWay collaborates with leading scientists and academic research institutions worldwide in clinical trials covering various neuropsychiatric and neuroscience applications.

The company’s technology has already helped thousands of patients worldwide regain well-being in private clinics, hospitals, and clinical studies.